-- Abraxis, Argon ST, Ford, Halliburton, Mela, SuperGen: U.S. Equity Movers
-- Nikolaj Gammeltoft
-- 2010-06-30T20:08:32Z
-- http://www.bloomberg.com/news/2010-06-29/enterprise-medtronic-peabody-zimmer-u-s-equity-preview.html

          
          
             Shares of the following companies
had unusual moves in U.S. trading. Stock symbols are in
parentheses, and prices are as of 4 p.m. in New York.  
 Companies involved in trying to halt the flow of oil from a
ruptured  BP Plc  (BP US) well in the Gulf of Mexico rallied after
the first hurricane of the season headed away from the area.  
 BP increased 4.4 percent to $28.88.  Anadarko Petroleum
Corp.  (APC US), the Texas oil company that owns a 25 percent
stake in BP’s well, fell 1.9 percent to $35.97.  Halliburton Co. 
(HAL US) advanced 0.3 percent to $24.55.  
 Other oil drillers also gained.  Baker Hughes Inc.  (BHI US)
increased 1.8 percent to $41.57.  Diamond Offshore Drilling Inc. 
(DO US) rose 3.4 percent to $62.22.  
 Abraxis BioScience Inc.  (ABII US) surged 21 percent to
$74.20, the highest price since December 2008.  Celgene Corp. 
(CELG US), the maker of blood cancer drugs, agreed to buy
Abraxis for $2.9 billion to acquire a solid-tumor medicine.
Celgene lost 4.2 percent to $51.  
 Acuity Brands Inc.  (AYI US) dropped 11 percent, the most
since October 2008, to $36.39. The maker of Gotham lighting
fixtures reported third-quarter earnings excluding some items of
48 cents a share, missing the average analyst estimate by 14
percent.  
 Argon ST Inc.  (STST US) rose 40 percent, the most since
April 2006, to $34.29. Boeing Co. (BA US) agreed to buy the
defense contractor in a deal valued at about $775 million,
expanding the planemaker’s reach into the market for military
electronics.  
 Ford Motor Co.  (F US) advanced 2 percent, the most in two
weeks, to $10.08. Ford will pay about $3.8 billion in cash to a
union health-care fund, a sign the automaker is confident that
Chief Executive Officer  Alan Mulally ’s focus on the namesake
brand will produce profits.  
 Mela Sciences Inc.  (MELA US) dropped 10 percent, the most
since March 25, to $7.44. The maker of medical devices sold 2.2
million shares for $7.50 each in a deal that may dilute the
value of existing shares.  
 SuperGen Inc.  (SUPG US) fell 13 percent, the most since
July 2008, to $2.02. The drugmaker said its leukemia treatment
Dacogen failed to show a statistically significant improvement
in survival rates.  
 To contact the reporter on this story:
 Nikolaj Gammeltoft  in New York at 
 ngammeltoft@bloomberg.net .  
          
          


  


        